Table 1. Characteristics and disease-free survival rate in 284 gastric cancer patient undergoing potentially curative surgery from 2000 to 2014 at Second University of Naples.
| Patients(%) | Recurrences(%) | 5yrDFS | HR | 95% CI * | P † | ||
|---|---|---|---|---|---|---|---|
| Age (years) ‡ | ≤ 63 | 144(51) | 50(35) | 62.9 | 1 | Referent | 0.61 |
| > 63 | 140(49) | 46(33) | 62.0 | 1.10 | 0.60-1-35 | ||
| Gender | Male | 170(60) | 50(29) | 67.9 | 1 | Referent | 0.07 |
| Female | 114(40) | 46(40) | 54.0 | 1.43 | 0.96–2.14 | ||
| Serum CEA Levels (ng/mL) | ≤ 3.5 | 228(80) | 64(28) | 69.8 | 1 | Referent | < 0.001 |
| > 3.5 | 56(20 | 32(62) | 33.7 | 2.55 | 1.67–3.90 | ||
| Performance Status | 0 | 114(40) | 36(32) | 66.2 | 1 | Referent | |
| 1 | 132(46) | 48(36) | 60.2 | 1.26 | 0.82–1.95 | 0.32 | |
| 2 | 38(14) | 12(32) | 55.8 | 1.58 | 0.82–3.05 | ||
| Tumor Site | Distal | 112(39) | 28(25) | 72.1 | 1 | Referent | |
| Middle Third | 104(37) | 44(42) | 53.0 | 2.04 | 1.27–3.27 | 0.013 | |
| Upper Third | 68(24) | 24(35) | 60.3 | 1.57 | 0.91–2.71 | ||
| Resection | Distal Gastrec. | 78(27) | 14(18) | 78.7 | 1 | Referent | 0.001 |
| Total Gastrec. | 206(73) | 82(40) | 56.2 | 2.56 | 1.45–4.52 | ||
| Macroscopic Type § | Mass | 48(17) | 2(4) | 95.2 | 1 | Referent | |
| Ulcerative | 116(41) | 32(28) | 70.0 | 7.43 | 1.78–31.03 | < 0.001 | |
| Ulcer-Infiltrat. | 92(32) | 44(48) | 47.6 | 12.84 | 3.11–53.00 | ||
| Diff.-Infiltrat. | 28(10) | 18(64) | 34.6 | 20.38 | 4.72–87.91 | ||
| Hystological Type ║ | Differentiated | 170(60) | 48(28) | 68.9 | 1 | Referent | 0.001 |
| Undifferent. | 114(40) | 48(42) | 51.6 | 1.66 | 1.21–2.27 | ||
| Lauren's Classification | Intestinal | 160(56) | 44(27) | 69.4 | 1 | Referent | 0.004 |
| Diffuse | 124(44) | 52(42) | 53.0 | 1.81 | 1.21–2.71 | ||
| Tumor Depth (T) | 1a | 14(5) | 0(0) | 100.0 | |||
| 1b | 32(11) | 2(6) | 92.9 | 1 | Referent | ||
| 2 | 58(20) | 2(3) | 96.2 | 0.50 | 09.71–3.59 | ||
| 3 | 56(21) | 30(53) | 42.5 | 12.08 | 2.88–50.59 | < 0.001 | |
| 4a | 112(39) | 56(50) | 43.5 | 10.85 | 2.64–44.50 | ||
| 4b | 12(4) | 6(50) | 50.0 | 10.35 | 2.08–51.33 | ||
| Serosal Invasion | S- | 160(56) | 34(21) | 76.6 | 1 | Referent | < 0.001 |
| S+ | 124(44) | 62(50) | 43.9 | 2.89 | 1.90–4.40 | ||
| Node Stage (N) | 0 | 148(52) | 22(15) | 83.2 | 1 | Referent | |
| 1 | 52(18) | 22(42) | 55.8 | 3.14 | 1.74–5.68 | ||
| 2 | 48(17) | 22(46) | 43.4 | 3.56 | 1.97–6.44 | < 0.001 | |
| 3a | 22(8) | 20(91) | 9.1 | 10.86 | 5.86–20.13 | ||
| 3b | 14(5) | 10(71) | 21.4 | 10.33 | 4,86–21.96 | ||
| New Node Stage (NewN) | 0 | 148(52) | 22(15) | 83.2 | 1 | Referent | |
| 1 | 57(20) | 15(26) | 73.3 | 1.79 | 0.93–3.45 | < 0.001 | |
| 2 | 36(13) | 20(55) | 29.9 | 5.26 | 2.87–9.66 | ||
| 3 | 43(15) | 39(91) | 9.3 | 10.40 | 6.11–17.71 | ||
| Node Position ¶ | None | 148(52) | 22(15) | 83.2 | 1 | Referent | |
| LC | 29(10) | 7(24) | 75.9 | 1.71 | 0.73–4.01 | ||
| GC | 28(8) | 8(28) | 70.6 | 1.86 | 0.83–4.20 | ||
| EP | 0(0) | 0(0) | 0 | 0.00 | 0.00–0.00 | < 0.001 | |
| LC+GC | 9(4) | 5(55) | 44.4 | 5.73 | 2.17–15.16 | ||
| LC+EP | 15(6) | 8(53) | 25.4 | 4.44 | 1.97–9.98 | ||
| GC+EP | 12(5) | 7(58) | 22.9 | 6.23 | 2.65–14.63 | ||
| LC+GC+EP | 43(15) | 39(91) | 9.3 | 10.42 | 6.12–17.74 | ||
| TNM Stage | IA | 40(14) | 0(0) | 100.0 | |||
| IB | 44(15) | 2(4) | 95.2 | 1 | Referent | ||
| IIA | 36(13) | 6(17) | 82.4 | 4.34 | 0.87–21.52 | ||
| IIB | 44(15) | 14(32) | 62.3 | 8.79 | 1.99–38.73 | < 0.001 | |
| IIIA | 50(18) | 26(52) | 45.5 | 16.00 | 3.79–67.44 | ||
| IIIB | 50(18) | 34(68) | 27.9 | 24.89 | 5.97–103.78 | ||
| IIIC | 20(7) | 14(70) | 18.0 | 31.50 | 7.11–139.45 | ||
| New TNM Stage | IA | 40(14) | 0(0) | 100.0 | |||
| IB | 45(16) | 1(2) | 97.7 | 1 | Referent | ||
| IIA | 35(12) | 7(20) | 78.8 | 10.71 | 1.31–87.11 | ||
| IIB | 48.17 | 12(25) | 71.2 | 13.53 | 1.75–104.08 | < 0.001 | |
| IIIA | 40(14) | 20(50) | 46.4 | 31.40 | 4.21–234.07 | ||
| IIIB | 55(19) | 37(67) | 25.7 | 55.05 | 7.54–401.73 | ||
| IIIC | 21(8) | 19(90) | 9.5 | 76.27 | 10.18–571.44 | ||
| No. of Resected Nodes ‡ | ≤ 27 | 150(53) | 46(31) | 66.3 | 1 | Referent | 0.31 |
| > 27 | 134(47) | 50(37) | 57.8 | 1.23 | 0.82–1.84 | ||
| PO Complications ║ | No | 222(78) | 68(31) | 66.8 | 1 | Referent | < 0.001 |
| Yes | 62(22) | 28(45) | 42.5 | 2.40 | 1.51–3.73 | ||
| PO Chemotherapy | No | 102(36) | 18(18) | 79.8 | 1 | Referent | 0.001 |
| Yes | 182(64) | 78(43) | 54.0 | 2.36 | 1.41–3.94 |
CEA indicates carcinoembryonic antigen (normal value ≤ 3.5 ng/mL). Performance status according to the ECOG scale; postoperative complications were defined as grade II or higher of the Clavien-Dindo classification (ref. n° 33)
* 95% confidence interval
† Kaplan-Meier method
‡ median value
§ according to Bormann's classification;
║ differentiated includes grading 1 and 2 tumors; undifferentiated includes grading 3 tumors and signet-ring cell cancers
¶ LC lesser curvature nodes (nodal groups 1, 3, and 5); GC greater curvature nodes (nodal groups 2, 4sa, 4sb, 4d, 6, and greater omentum); EP extra-perigastric nodes (nodal groups 7, 8a, 9, 10, 11p, 11d, and 12a)